Krajina: Izrael
Jazyk: angličtina
Zdroj: Ministry of Health
DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE
MEDISON PHARMA LTD
C01BA01
CAPSULES
QUINIDINE SULFATE 10 MG; DEXTROMETHORPHAN HYDROBROMIDE 20 MG
PER OS
Required
AVANIR PHARMACEUTICALS, USA
QUINIDINE
For the treatment of Pseudobulbar Affect (PBA) .
2018-05-31
PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS (PREPARATIONS) 1986 This medicine is dispensed with a doctor’s prescription only NUEDEXTA CAPSULES ACTIVE INGREDIENTS: DEXTROMETHORPHAN HYDROBROMIDE 20 MG AND QUINIDINE SULFATE 10 MG INACTIVE INGREDIENTS: See the section “Important information about some of this medicine’s ingredients” and section 6 “Additional information”. READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. This leaflet contains concise information about this medicine. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed to treat your illness. Do not pass it on to others. It may harm them, even if it seems to you that their illness is similar. 1. WHAT IS THIS MEDICINE INTENDED FOR? Nuedexta is intended for the treatment of pseudobulbar affect (PBA), a secondary effect to a variety of neurological disorders, unrelated to each other, characterized by involuntary, sudden and frequent events of crying and/or laughing. PBA events are characterized by their occurrence being unrelated to the underlying emotional state of the patient. THERAPEUTIC GROUP: medicinal products acting on the nervous system. 2. BEFORE USING THIS MEDICINE DO NOT USE THIS MEDICINE: If you are sensitive (allergic) to the active ingredients or to any of the other ingredients that this medicine contains (See section 6). In certain cases of cardiovascular disorders and in patients with heart failure. If you have previously suffered from thrombocytopenia caused by using Nuedexta, quinine, mefloquine or quinidine. If you have previously suffered from hepatitis. If you have previously suffered from bone marrow suppression; or lupus-like symptoms. In combination therapy with medicines containing quinidine, quinine, mefloquine. In combination therapy with monoamine oxidase inhibitors or if you have taken medicines in the monoamine oxidase inhibitor class within the 14 days preceding this treatment. In addition, you should wait 14 days after you Prečítajte si celý dokument
[לוגו מדינת ישראל] [http://www.gov.il/] [http://www.gov.il/] [לוגו משרד הבריאות] [לוגו משרד הבריאות] [*5400] [http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx] [http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx] הציבור הרחב עסקים ומוסדות עובדים בבריאות חפש מידע תפריט * [סגירה] סגור * דף הבית [http://www.health.gov.il/] * אודות * אודות המשרד [http://www.health.gov.il/About/Pages/about_us.aspx] * תוכנית עבודה [http://www.health.gov.il/About/Pages/Agenda.aspx] * תקציב המשרד [http://www.health.gov.il/About/Pages/budget.aspx] * תרשים מבנה ארגוני [http://www.health.gov.il/About/Pages/OrganizationalStructureDiagram.aspx] * בעלי תפקידים [http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx] * יחידות המשרד [http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] * לשכות הבריאות [http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx?tab=3] * אמנת שירות [http://www.health.gov.il/About/sla/Pages/default.aspx] * אותות ופרסים [http://www.health.gov.il/About/Awards/Pages/mifal.aspx] * פרוייקטים תשתיתיים [http://www.health.gov.il/About/projects/shared_medical_info/Pages/default.aspx] * דרושים [http://www.health.gov.il/About/Careers/Pages/default.aspx] * מנכ"לי משרד הבריאות לדורותיהם [http://www.health.gov.il/About/Pages/GeneralManegerHistory.aspx] * יחידות המשרד * יחידות המשרד [http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] * לשכות הבריאות [http://www.health.gov.il/UnitsOffice/LB/Pages/default.aspx] * וועדות ומועצות [http://www.health.gov.il/Services/Committee/Pages/CommitteeList.aspx] * נושאים * בריאות הנפש [http://www.health.gov.il/Subjects/mental_health/Pages/default.aspx] * בריאות הסביבה [http://www.health.gov.il/Subjects/Environmental_Health/ Prečítajte si celý dokument